Now I have enough to write a comprehensive earnings preview. Let me compile this into markdown format.# CVS Health (CVS) — Q2 2026 Earnings Preview Report Date: August 5, 2026 (before market open) | Current Price: ~$104-105 | YTD Performance: +~30%
CVS shares have been on a strong run heading into this print, climbing from roughly $80 at the start of 2026 to the mid-$100s by early August, with a notable leg up following the Q1 report on May 6 (the stock jumped from ~$80 to nearly $87 that day and continued climbing into the $100–$110 range through June and July). Sentiment has shifted decisively positive as the market has bought into management's multi-year Aetna margin-recovery narrative. Consensus expects adjusted EPS of roughly $1.85–$1.87 (vs. $1.81 a year ago) on revenue of roughly $100.2 billion, which would be essentially flat year-over-year, a deceleration from the 8.4% growth posted in the prior-year quarter. Wall Street's average price target sits around $107–$115, and the sell-side consensus rating remains solidly bullish. Notably, CVS has beaten EPS estimates in each of the last four quarters, with an average beat of nearly 16%, so the bar going into tomorrow is arguably elevated by its own track record.
Q1 2026 was the catalyst for the current rally, and it set the tone for what investors will be looking for tomorrow. In Q1, CVS delivered adjusted EPS of $2.57, a meaningful increase of over 14% from the prior year quarter, on cash flow from operations of approximately $4.2 billion, and total revenue over $100 billion, an increase of over 6%. Critically, management raised full-year guidance meaningfully: first quarter performance gave the confidence to increase full year 2026 adjusted EPS guidance to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20.
The engine of that beat was Aetna. The Health Care Benefits segment's adjusted operating income increased 52.6% for the three months ended March 31, 2026, compared to the prior year, primarily driven by improved underlying performance in the Government business, while the MBR decreased to 84.6% in the three months ended March 31, 2026, compared to 87.3% in the prior year. Investors should note this improvement was flattered by favorable reserve development: prior years' health care costs payable estimates developed favorably by $1.1 billion during the three months ended March 31, 2026. Management was careful to frame this as one-time in nature — CFO Brian Newman noted the Q1 outperformance benefited from favorable prior year development primarily in the government business, and pockets of core outperformance driven by strong medical cost management, which has not been reflected in guidance because it's only the first quarter — meaning the bar for organic MBR improvement in Q2 is a genuine tell on whether the Aetna turnaround is durable or partly a reserve-release story.
Health Care Benefits (Aetna) — the swing factor. Full-year guidance calls for enterprise adjusted operating income of approximately $4 billion to $4.34 billion, an increase of $420 million relative to prior guidance, reflecting the favorable prior year development experienced in the first quarter, while the company continues to expect a full year MBR within its previous guidance range of 90.5%, plus or minus 50 basis points. Investors will want to see continued sequential improvement in medical cost trend, particularly in Medicare Advantage, where management has been explicit that the business improved significantly in 2025 but, like most of the industry, still generated an adjusted operating loss, and that the April 2026 CMS Final Rate Notice represented a step in the right direction toward greater sustainability but remains insufficient to offset underlying medical cost trends. Management has reiterated a path to Medicare Advantage target margins by 2028, with Aetna leadership stating confidence in continuing the momentum and making meaningful progress towards target margins in 2027, and reaffirming confidence in hitting target margins in 2028. Peer read-throughs are favorable here: UnitedHealth, Humana and Cigna shares all rallied around their own Q2 prints on softer medical cost trends, and UnitedHealth posted a Q2 medical cost ratio of 86.7%, "reflecting cost and pricing discipline."
Health Services (Caremark/PBM) — rebate guarantee execution. This segment's adjusted operating income actually declined 7% in Q1 due to client price concessions, though management called out that results included an early "pull-forward" of value from Q2, and that excluding that timing benefit, the segment still modestly beat expectations. Watch for commentary on whether the pull-forward creates a tougher Q2 comparison, and for updates on rebate-guarantee performance — management said in Q1 they expected this to be "reflected in our 2026 outlook with no surprises." Also watch for GLP-1/specialty drug commentary and any impact from the STELARA biosimilar formulary exclusion effective July 1, 2026, which management is targeting for HUMIRA-like (>90%) conversion economics.
Pharmacy & Consumer Wellness (retail) — steady but margin-pressured. Q1 adjusted operating income fell 9% on reimbursement pressure, weather/seasonal illness headwinds, and continued investment spend, even as same-store pharmacy sales and prescription volumes grew. Full-year guidance was nonetheless raised slightly to at least $6.18 billion, an increase of approximately $90 million from prior guidance. Watch for updates on the Rite Aid asset integration, Omnicare deconsolidation effects on comparability, and GLP-1 direct-to-consumer volume trends (the company cited a 200bps share gain in that category in Q1).
CVS ended Q1 with leverage improved to 3.84x, and management has been focused on delivering that reduction before flipping capital priorities. On the Q1 call, CFO Newman said buybacks are not baked into the '26 guide, but the company will evaluate the impact of improving financial performance and leverage throughout '26, as well as potential capital deployment opportunities later this year. The board has continued its 56-year dividend streak, declaring a $0.665/share quarterly dividend in July. Given leverage has reportedly moved into the low-3x range (below the company's BBB target), any signal on resuming buybacks would likely be read as a bullish incremental catalyst tomorrow.
Full-year 2026 guidance currently stands at: - Adjusted EPS: $7.30–$7.50 (raised from $7.00–$7.20 after Q1) - Revenue: at least $405 billion - Cash flow from operations: at least $9.5 billion - Enterprise adjusted operating income: $15.53–$15.87 billion, with a guided 60/40 first-half/second-half earnings split
That 60/40 split is an important framing detail: it implies the market already expects H1 to carry more of the annual earnings weight, so a Q2 beat alone may not be enough — investors will be parsing whether full-year guidance moves again, and by how much, similar to the $0.30 raise after Q1.
Going into tomorrow's print, the setup is one of elevated expectations after a genuine fundamental inflection at Aetna, a stock re-rating that has already priced in a good chunk of the turnaround (shares up roughly 30% YTD and near 52-week highs), and consensus estimates that have been "reconfirmed" rather than raised over the past 30 days — suggesting the sell-side sees this as a "stay the course" quarter rather than a fresh re-acceleration. The key swing factors are: (1) whether the medical benefit ratio and Medicare Advantage trajectory continue improving on an organic basis (versus reserve releases), (2) whether Health Services can show durable margin stabilization following the Q1 pull-forward, (3) any incremental guidance raise, and (4) any signal on capital return/buyback resumption given improved leverage. Given how far the stock has run, the market's reaction is likely to hinge less on a beat-or-miss against consensus EPS and more on the tone of forward commentary on Aetna's path to target margins and 2027 planning.